Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, PTC Therapeutics, Inc. reported revenue of $1.73B, up 114.5% year over year. Operating margin was 50.1% and net margin 39.4%, on a free-cash-flow margin of 40.6% with capital expenditure at 0.5% of revenue. Every figure is computed directly from PTCT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $1.73B | 50.1% | 39.4% |
| FY2024 | $807M | -37.5% | -45.0% |
| FY2023 | $938M | -46.9% | -66.8% |
| FY2022 | $699M | -64.0% | -80.0% |
| FY2021 | $539M | -69.5% | -97.3% |
How does PTCT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.